Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-15), Oncoinvent ASA's 3-1 Month Momentum % is N/A%.
The industry rank for Oncoinvent ASA's 3-1 Month Momentum % or its related term are showing as below:
BRRGF's 3-1 Month Momentum % is not ranked *
in the Biotechnology industry.
Industry Median: 1.6 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Oncoinvent ASA 3-1 Month Momentum % Related Terms
BRRGF vs VRTX, REGN, MRNA: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Oncoinvent ASA's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncoinvent ASA 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncoinvent ASA's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Oncoinvent ASA's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncoinvent ASA (BRRGF) has a 3-1 Month Momentum % of N/A% as of Sep. 15, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oncoinvent ASA and its competitors. According to the industry distribution chart, Oncoinvent ASA ranks #24 out of 1380 companies in the Biotechnology industry, placing it in the top 1.7%.
Is Oncoinvent ASA's 3-1 Month Momentum % too high?
Oncoinvent ASA's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Oncoinvent ASA ranks #24 out of 1380 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Oncoinvent ASA has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Oncoinvent ASA's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oncoinvent ASA ranks #24 out of 1380 companies for 3-1 Month Momentum %. This places Oncoinvent ASA in the top 2% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
The median 3-1 Month Momentum % among Biotechnology companies is 1.60, based on 1,380 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Oncoinvent ASA and its competitors. For the Biotechnology industry, the median 3-1 Month Momentum % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncoinvent ASA's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncoinvent ASA stock overvalued right now?
Oncoinvent ASA (BRRGF) has a current 3-1 Month Momentum % of N/A%. The stock's GF Value™ is $160.69, compared to a current price of $97.09 — trading 39.6% below its estimated fair value. The current 3-1 Month Momentum % is N/A%. Oncoinvent ASA's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Oncoinvent ASA (BRRGF), the current 3-1 Month Momentum % is N/A% as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncoinvent ASA (BRRGF) Overvalued in 2026?
Based on GuruFocus' analysis, Oncoinvent ASA stock appears to be undervalued.
The current stock price of $97.09 is trading 39.6% below its estimated GF Value™ of $160.69.
Key valuation signals for BRRGF:
3-1 Month Momentum %: N/A%
GF Value™: $160.69 vs. price of $97.09 (39.6% below fair value)
No single metric tells the full story. See the BRRGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncoinvent ASA is a clinical-stage biotechnology company developing novel radiopharmaceutical therapies against cancer. Its key product candidate is Radspherin, a receptor-independent alpha radiation therapy that leverages the anatomy of the abdominal cavity to destroy residual micrometastases using a single, localized dose of alpha radiation. Radspherin is currently in clinical development in two indications: peritoneal metastasis from ovarian and colorectal cancer, but it is also relevant for treating peritoneal metastasis from other cancer types and potentially metastatic cancer in other body cavities. Geographically, the company operates in Norway.
52GF Score
Get the complete analysis for BRRGF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRRGF has been successfully added to your 
